Apr 22, 2015 8:00 am EDT Heat Biologics, Inc. to Present at the 2015 American Association for Cancer Research Annual Meeting
Apr 15, 2015 8:00 am EDT Heat Biologics, Inc. to Present at the 2015 American Association for Cancer Research Annual Meeting
Mar 27, 2015 8:30 am EDT Heat Biologics Announces Financial Results for the Year Ended December 31, 2014
Mar 16, 2015 2:28 pm EDT Heat Biologics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Over-Allotment Option
Mar 10, 2015 9:42 pm EDT Heat Biologics, Inc. Announces Pricing of Public Offering of $10,660,000 of Common Stock
Mar 09, 2015 8:00 am EDT Heat Biologics, Inc. Receives US FDA Fast Track Designation for HS-410 (Vesigenurtacel L) in Combination With BCG for the Treatment of Non-Muscle Invasive Bladder Cancer
Feb 23, 2015 8:00 am EST Heat Biologics, Inc. to Host Key Opinion Leader Meeting on February 26 in New York City
Feb 18, 2015 6:00 am EST Heat Biologics, Inc. and OncoSec Medical Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms